RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, has announced execution of definitive agreements for a seed round financing of $10 million.

RNAimmune is a spin-off entity from Sirnaomics, a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases.

Smooth River and Hong Kong Hongrun led the investment, with participation from Shanghai Walga Biotechnology, High Forest Investment and Terra Magnum Sigma. Sirnaomics also increased its investment in RNAimmune.

This financing will allow RNAimmune to accelerate its research and development into mRNA vaccine and drug discovery focused on infectious disease, cancer, and rare diseases.

Since its founding in early 2020, RNAimmune has built up its mRNA vaccine and drug discovery and development platform to tackle high unmet medical needs in infectious diseases, cancer and rare diseases.

The Company is now in the IND enabling stage for its lead candidate COVID-19 mRNA vaccine and plans to file an IND with the U.S. Food and Drug Administration before the end of 2021.

It is also advancing its RAS tumor vaccine program in collaboration with the University of California, Los Angeles. Headquartered in Maryland, United States, RNAimmune has set up its China R&D center in Guangzhou Bio-Island. Last August, the Company completed a seed financing round of $2.35 million.